Joshua A Fein
Overview
Explore the profile of Joshua A Fein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
379
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Fein J, Shouval R, Galimard J, Labopin M, Socie G, Finke J, et al.
Blood Adv
. 2023 Jan;
7(10):2143-2152.
PMID: 36622338
Older age and a high burden of comorbidities often drive the selection of low-intensity conditioning regimens in allogeneic hematopoietic stem cell transplantation recipients. However, the impact of comorbidities in the...
12.
Fried S, Shouval R, Walji M, Flynn J, Yerushalmi R, Shem-Tov N, et al.
Transplant Cell Ther
. 2022 Nov;
29(2):99-107.
PMID: 36343892
Anti-CD19 chimeric antigen receptor T cell (CAR-T) therapy has transformed the care of patients with relapsed/refractory large B cell lymphoma (LBCL). However, approximately 60% of CAR-T recipients ultimately will experience...
13.
Tomas A, Fein J, Fried S, Flynn J, Devlin S, Fingrut W, et al.
Leukemia
. 2022 Nov;
37(1):154-163.
PMID: 36335261
Persistence or recurrence of large B-cell lymphoma after CD19-CAR-T is common, yet data guiding management are limited. We describe outcomes and features following CAR-T treatment failure. Of 305 adults who...
14.
Fried S, Shouval R, Varda-Bloom N, Besser M, Yerushalmi R, Shem-Tov N, et al.
Leuk Lymphoma
. 2022 Sep;
63(14):3385-3393.
PMID: 36111694
Tisagenlecleucel (tisa-cel) is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for patients with relapsed/refractory large B-cell lymphoma. Outcomes of patients with out-of-commercial specification (OOS) CAR T products are...
15.
Nath K, Tomas A, Flynn J, Fein J, Alperovich A, Anagnostou T, et al.
Transplant Cell Ther
. 2022 Aug;
28(11):751.e1-751.e7.
PMID: 35944603
Vitamin D insufficiency is a potentially modifiable risk factor for poor outcomes in newly diagnosed large B-cell lymphoma (LBCL). However, the role of circulating vitamin D concentrations in relapsed/refractory LBCL...
16.
Shouval R, Tomas A, Fein J, Flynn J, Markovits E, Mayer S, et al.
J Clin Oncol
. 2021 Dec;
40(4):369-381.
PMID: 34860572
Purpose: Tumor-intrinsic features may render large B-cell lymphoma (LBCL) insensitive to CD19-directed chimeric antigen receptor T cells (CAR-T). We hypothesized that TP53 genomic alterations are detrimental to response outcomes in...
17.
Eshel A, Sharon I, Nagler A, Bomze D, Danylesko I, Fein J, et al.
Blood Adv
. 2021 Oct;
6(2):568-573.
PMID: 34644375
We observed high rates of bloodstream infections (BSIs) following fecal microbiota transplantation (FMT) for graft-versus-host-disease (33 events in 22 patients). To trace the BSIs' origin, we applied a metagenomic bioinformatic...
18.
Shouval R, Fein J, Cho C, Avecilla S, Ruiz J, Tomas A, et al.
Blood Adv
. 2021 Sep;
6(5):1525-1535.
PMID: 34507354
Individual comorbidities have distinct contributions to nonrelapse mortality (NRM) following allogeneic hematopoietic cell transplantation (allo-HCT). We studied the impact of comorbidities individually and in combination in a single-center cohort of...
19.
Geva M, Pryce A, Shouval R, Fein J, Danylesko I, Shem-Tov N, et al.
Bone Marrow Transplant
. 2021 Jun;
56(11):2690-2696.
PMID: 34188181
Risk stratification is important for balancing potential risks and benefits of allogeneic hematopoietic stem cell transplantation (HSCT) for hematological malignancies. We retrospectively studied 1119 patients undergoing allogenic-HSCT in a single...
20.
Shouval R, Fein J, Labopin M, Cho C, Bazarbachi A, Baron F, et al.
Lancet Haematol
. 2021 Feb;
8(3):e205-e215.
PMID: 33636142
Background: Diagnosis and remission status at the time of allogeneic haematopoietic stem-cell transplantation (HSCT) are the principal determinants of overall survival following transplantation. We sought to develop a contemporary disease-risk...